Revvity (RVTY) Stock Price, News & Analysis

Company Overview

Revvity, Inc. (NYSE:RVTY) is a life sciences and diagnostics company that provides technologies, products and services used in biological research, drug discovery, clinical testing and healthcare. The company serves pharmaceutical and biotechnology companies, academic and government research institutions, hospitals, clinical laboratories and other healthcare organizations.

Its portfolio includes instruments, reagents, consumables, software and related services for areas such as genomics, proteomics, cellular analysis, imaging and multiplex testing. Revvity also supports reproductive health and newborn screening, infectious disease testing, and workflows used to identify and monitor diseases and evaluate potential therapies.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its life sciences and diagnostics operations. Based in Waltham, Massachusetts, the company serves customers internationally through a global commercial and support network. Prahlad Singh serves as president and chief executive officer.

Key Stats

• Today's Range: $153.10 to $157.46
• 50-Day Range: $111.06 to $157.14
• 52-Week Range: $81.22 to $166.25
• Volume: 1.39 million shs
• Average Volume: 1.51 million shs
• Market Capitalization: $17.30 billion
• P/E Ratio: 73.85
• Dividend Yield: 0.18%
• Price Target: $124.43
• Consensus Rating: Hold

Revvity Stock Analysis - MarketRank™

Revvity scored higher than 48% of companies evaluated by MarketBeat, and ranked 585th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Revvity has received a consensus rating of Hold. The company's average rating score is 2.26, and is based on no strong buy ratings, 5 buy ratings, 14 hold ratings, and no sell ratings.

Downside Risk

Revvity has a consensus price target of $124.43, representing about 20.1% downside from its current price of $155.82.

Amount of Analyst Coverage

Revvity has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 10.07%

Earnings Growth

Earnings for Revvity are expected to grow by 10.07% in the coming year, from $5.36 to $5.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revvity is 74.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revvity is 74.28, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.82.

Price to Earnings Growth Ratio

Revvity has a PEG Ratio of 2.80. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Revvity has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.70% of the float of Revvity has been sold short.

Short Interest Ratio / Days to Cover

Revvity has a short interest ratio ("days to cover") of 2.42, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Revvity has recently increased by 1.37%, indicating that investor sentiment is decreasing.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Revvity has a dividend yield of 0.18%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Revvity does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Revvity is 13.33%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Revvity will have a dividend payout ratio of 4.75% next year. This indicates that Revvity will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.02

News Sentiment

Revvity has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Revvity this week, compared to 5 articles on an average week.

Search Interest

7 people have searched for RVTY on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

5 people have added Revvity to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Revvity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,290,745.00 in company stock.

Percentage Held by Insiders

0.85% of the stock of Revvity is held by insiders.

Percentage Held by Institutions

86.65% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 8/7 Dividend: 7/17/2026
• Ex-Dividend for 8/7 Dividend: 7/17/2026
• Last Earnings: 8/04/2026
• Dividend Payable: 8/07/2026
• Today: 10/13/2026
• Record date for 11/13 Dividend: 10/23/2026
• Ex-Dividend for 11/13 Dividend: 10/23/2026
• Next Earnings (Confirmed): 11/03/2026
• Dividend Payable: 11/13/2026
• Investor Day 2026: 11/13/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:RVTY
• CIK: 31791
• Web: www.revvity.com
• Phone: (781) 663-6900
• Fax: 781-663-5985
• Employees: 11,000
• Year Founded: 1937

Price Target and Rating

• Average Price Target for Revvity: $124.43
• High Price Target: $175.00
• Low Price Target: $90.00
• Potential Upside/Downside: -19.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.26
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.10
• Trailing P/E Ratio: 73.85
• Forward P/E Ratio: 28.93
• P/E Growth: 2.8
• Net Income: $241.20 million
• Net Margins: 8.16%
• Pretax Margin: 8.96%
• Return on Equity: 8.34%
• Return on Assets: 5.01%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 1.80
• Quick Ratio: 1.50

Sales & Book Value

• Annual Sales: $2.91 billion
• Price / Sales: 5.94
• Cash Flow: $8.87 per share
• Price / Cash Flow: 17.49
• Book Value: $63.95 per share
• Price / Book: 2.43

Miscellaneous

• Outstanding Shares: 111,586,000
• Free Float: 110,638,000
• Market Cap: $17.30 billion
• Optionable: Optionable
• Beta: 1.06